カテゴリー： GlobalData, 世界, 医療/バイオ

急性骨髄性白血病（AML）の疫学的予測

【英語タイトル】EpiCast Report: Acute Myeloid Leukemia - Epidemiology Forecast to 2024

GlobalDataが出版した調査資料（GDHCER093-15）・商品コード：GDHCER093-15
・発行会社（調査会社）：GlobalData
・発行日：2015年10月8日
・ページ数：74
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール
・調査対象地域：グローバル
・産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD3,995 ⇒換算￥451,435見積依頼/購入/質問フォーム
Site License（同一国内共有可）USD7,990 ⇒換算￥902,870見積依頼/購入/質問フォーム
Enterprisewide License（複数国内共有可）USD11,985 ⇒換算￥1,354,305見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日～2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・郵送（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
当調査レポートでは、急性骨髄性白血病（AML）の疫学的市場予測について調査・分析し、以下の構成でお届けいたします。

・イントロダクション
・急性骨髄性白血病（AML）の概要
・リスク要因及び併存症
・主要地域の動向
・疫学的予測方法
・急性骨髄性白血病（AML）の疫学的予測結果（有病率など）
・考察（結論、分析の限界・強み）
【レポートの概要】

EpiCast Report: Acute Myeloid Leukemia – Epidemiology Forecast to 2024

Summary

Acute myeloid leukemia (AML), also known as myelogenous leukemia, acute myelocytic leukemia, or acute nonlymphocytic leukemia, is a rare cancer that accounts for a disproportionally high number of cancer-related deaths. The disease is more common in the elderly, and is relatively more common in men than in women.

Acute promyelocytic leukemia (APL) and myelodysplastic syndromes (MDS)/therapy-related AML are two subtypes of AML that are especially unique in terms of disease etiology and prognosis, both of which will be discussed in detail in this report. Additionally, AML is associated with molecular gene mutations that are distinct from chromosomal structural abnormalities; of these, the best-studied is the FLT3 mutation (NCI, 2013). AML cases can also be stratified into three prognostic risk groups for treatment planning: favorable, intermediate, and adverse.

GlobalData epidemiologists estimate that the 7MM had 40,661 diagnosed incident cases of AML in 2014, nearly half of which occurred in the US. In the next 10 years, the 7MM will experience an increase in disease burden at a rate of 2.03% per year, which will be driven by population increase; this will result in 48,918 diagnosed incident cases of AML in 2024. For 2014, the number of diagnosed prevalent cases of AML was nearly identical to the number of diagnosed incident cases, at 44,079 cases, thereby underlining the lethality and poor long-term survival of the disease. The development of more effective therapies, particularly for elderly patients, would improve survival and increase disease prevalence.

Scope

The Acute Myeloid Leukemia (AML) EpiCast Report provides an overview of the risk factors and global trends of AML in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiology forecast of the following segmentations in adults ages 20 years and older across the 7MM –
- Diagnosed incident cases of AML, segmented by sex and 10-year age groups
- Five-year diagnosed prevalent cases of AML, segmented by ages 20-59 years and ages 60 years and older
- Diagnosed incident and five-year diagnosed prevalent cases of APL and MDS/therapy-related AML, segmented by ages 20-59 years and ages 60 years and older
- Diagnosed incident cases of AML that have mutations in the FLT3 gene
- Diagnosed incident cases of AML classified into favorable, intermediate, and adverse risk groups
- The AML epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The Acute Myeloid Leukemia (AML) EpiCast series will allow you to –
- Develop business strategies by understanding the trends shaping and driving the global AML market.
- Quantify patient populations in the global AML market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for AML therapeutics in each of the markets covered.
- Identify the percentage of AML cases by age, subtype, and risk group.

【レポートの目次】

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 9
2.3 Upcoming Related Reports 9
3 Epidemiology 10
3.1 Disease Background 10
3.2 Risk Factors and Comorbidities 11
3.2.1 Increased age is associated with increased risk and worsened prognosis 12
3.2.2 Smoking increases the risk of M2 AML 13
3.2.3 APL is relatively common among Spanish and Italian origins 13
3.2.4 Chemotherapy and radiation therapy increases the risk of AML 14
3.2.5 Benzene increases risk of AML 14
3.3 Global Trends 15
3.3.1 Incidence 15
3.3.2 Survival and Prevalence 18
3.3.3 Subtypes and Mutations 19
3.3.4 Risk Groups 21
3.4 Forecast Methodology 24
3.4.1 Sources Used 25
3.4.2 Forecast Assumptions and Methods 32
3.4.3 Sources not Used 38
3.5 Epidemiological Forecast for Acute Myeloid Leukemia (2014-2024) 39
3.5.1 Adjusted Diagnosed Incident Cases of AML 39
3.5.2 Adjusted Diagnosed Incident Cases of AML by Age 41
3.5.3 Adjusted Diagnosed Incident Cases of AML by Sex 43
3.5.4 Age-Standardized Incidence of AML 44
3.5.5 APL and MDS/Therapy Related AML 45
3.5.6 APL and MDS/Therapy Related AML by Age 49
3.5.7 Diagnosed Incident Cases of AML with FLT3 Mutations 51
3.5.8 Diagnosed Incident Cases of AML by Risk Group Classifications 52
3.5.9 Five-Year Diagnosed Prevalent Cases of AML 55
3.5.10 Five-Year Diagnosed Prevalent Cases of AML by Age 57
3.5.11 Five-Year Diagnosed Prevalent Cases of APL and MDS/Therapy-Related AML 58
3.5.12 Five-Year Diagnosed Prevalent Cases of APL and MDS/Therapy-Related AML by Age 59
3.6 Discussion 60
3.6.1 Epidemiological Forecast Insight 60
3.6.2 Limitations of the Analysis 61
3.6.3 Strengths of the Analysis 62
4 Appendix 63
4.1 Bibliography 63
4.2 About the Authors 69
4.2.1 Epidemiologists 69
4.2.2 Reviewers 70
4.2.3 Global Director of Therapy Analysis and Epidemiology 70
4.2.4 Global Head of Healthcare 71
4.3 About GlobalData 72
4.4 About EpiCast 72
4.5 Disclaimer 73

1.1 List of Tables
Table 1: Risk Factors for AML in Adults 12
Table 2: Incidence of AML per 100,000 Population in Japan, 1993-2002, All Ages 17
Table 3: Estimated Frequencies of Cytogenetic Abnormalities in AML 22
Table 4: Risk Group Classification Guidelines 23
Table 5: 7MM, Sources of AML Diagnosed Incidence 25
Table 6: 7MM, Adjusted Diagnosed Incident Cases of AML, Both Sexes, Ages ≥20 Years, N, Selected Years, 2014-2024 40
Table 7: 7MM, Adjusted Diagnosed Incident Cases of AML by Age, Both Sexes, N (Row %), 2014 41
Table 8: 7MM, Adjusted Diagnosed Incident Cases of AML by Sex, N (Row %), 2014 43
Table 9: 7MM, Diagnosed Incident Cases of APL, Both Sexes, Ages ≥20 Years, N, Selected Years, 2014-2024 46
Table 10: 7MM, Diagnosed Incident Cases of MDS/Therapy-related AML, Both Sexes, Ages ≥20 Years, N, Selected Years, 2014-2024 47
Table 11: 7MM, Diagnosed Incident Cases of AML Subtypes by Age, Both Sexes, N (Row % in Each Subtype), 2014 49
Table 12: 7MM, Diagnosed Incident Cases of AML with FLT3 Mutations, Both Sexes, Ages ≥20 Years, N, Selected Years 2014-2024 51
Table 13: 7MM, Diagnosed Incident Cases of AML by Risk Group Classification, Both Sexes, Ages ≥20 Years, N (Row %), 2014 52
Table 14: US, Risk Group Classification of AML Incident Cases by Age, Both Sexes, N (Row %), 2014 54
Table 15: 7MM, Five-Year Diagnosed Prevalent Cases of AML, Both Sexes, Ages ≥20 Years, N, Selected Years, 2014-2024 55
Table 16: 7MM, Five-Year Diagnosed Prevalent Cases of AML by Age, Both Sexes, N (Row %), 2014 57
Table 17: 7MM, Five-Year Diagnosed Prevalent Cases of APL, Both Sexes, Ages ≥20 Years, N, Selected Years, 2014-2024 58
Table 18: 7MM, Five-Year Diagnosed Prevalent Cases of MDS/Therapy-Related AML, Both Sexes, Ages ≥20 Years, N, Selected Years, 2014-2024 59
Table 19: 7MM, Five-Year Diagnosed Prevalent Cases of AML Subtypes by Age, Both Sexes, N (Row %), 2014 60

1.2 List of Figures
Figure 1: 7MM, Adjusted Diagnosed Incident Cases of AML, Both Sexes, Ages ≥20 Years, N, 2014-2024 40
Figure 2: 7MM, Adjusted Diagnosed Incident Cases of AML by Age, Both Sexes, Ages ≥20 Years, N, 2014 42
Figure 3: 7MM, Adjusted Diagnosed Incident Cases of AML by Sex, Ages ≥20 Years, N, 2014 44
Figure 4: 7MM, Age-Standardized Adjusted Diagnosed Incidence of AML, Ages ≥20 Years, 2014 45
Figure 5: 7MM, Diagnosed Incident Cases of APL, and MDS/Therapy-Related AML, Both Sexes, Ages ≥20 Years, N, 2014 and 2024 48
Figure 6: 7MM, Diagnosed Incident Cases of AML Subtypes by Age, Both Sexes, N, 2014 50
Figure 7: 7MM, Diagnosed Incident Cases of AML by Risk Group Classification, Both Sexes, Ages ≥20 Years, N, 2014 53
Figure 8: US, Risk Group Classification of AML Incident Cases by Age, Both Sexes, N, 2014 54
Figure 9: 7MM, Five-Year Diagnosed Prevalent Cases of AML, Both Sexes, Ages ≥20 Years, N, 2014-2024 56

【レポートのキーワード】

急性骨髄性白血病（AML）、疫学調査

★調査レポート[急性骨髄性白血病（AML）の疫学的予測] (コード：GDHCER093-15)販売に関する免責事項を必ずご確認ください。
★調査レポート[急性骨髄性白血病（AML）の疫学的予測]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 心不全の世界市場：疫学予測
    GDHCER150-17 / GlobalData / 2017年6月12日 / ...EpiCast Report: Heart Failure - Epidemiology Forecasts to 2026 Summary Heart failure (HF), also referred to as congestive cardiac failure, is a heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic needs of the body. Eventually, without the heart's pumping action to deliver oxygen and nutrient-rich blood to the cells, fatigue, shortness of breath, and coughing results. Even everyday activities such as walking, climbing stairs, or carrying weight can become tedious. To forecast the diagnosed incident cases of HF and diagnosed prevalent cases of chronic HF (CHF) in the 7MM, GlobalData epidemiologists...
  • 急性骨髄性白血病の疫学予測（～2026年）
    GDHCER153-17 / GlobalData / 2017年7月1日 / ...EpiCast Report: Acute Myeloid Leukemia - Epidemiology Forecast to 2026 Summary Acute myeloid leukemia (AML) is a rare cancer that accounts for a disproportionally high number of cancer-related deaths. The disease is more common in the elderly, and is relatively more common in men than in women. AML progresses quickly, has low survival rates, and has high rates of relapse, even with treatment. The cause of AML is unknown, but an increased risk of the disease is associated with factors such as age, male sex, a history of smoking, and exposure to high doses of radiation and cytotoxic chemicals. Due...
  • 移植片対宿主病（GVHD）の疫学予測
    DELV803010 / DelveInsight / 2018年3月 / ...DelveInsight’s ‘Graft versus Host Disease (GvHD) - Epidemiology Forecast to 2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Graft versus Host Disease (GvHD) in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan. Geography Covered • The United States • EU5 (Germany, France, Italy, Spain and the United Kingdom) • Japan Study Period: 2016-2027 Graft versus Host Disease (GvHD) Epidemiology The Graft versus Host Disease (GvHD) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. The epidemiology data for Graft...
  • 血友病の世界市場：疫学予測
    GDHCER151-17 / GlobalData / 2017年7月1日 / ...EpiCast Report: Hemophilia - Epidemiology Forecast to 2026 Summary Hemophilia is an X-linked hereditary bleeding disorder characterized by impaired blood coagulation as a result of deficiencies in the production or function of coagulation factor VIII (FVIII) in hemophilia A, or factor IX (FIX) in hemophilia B. Because of the deficiency of coagulation factor, hemophilia patients have a tendency for bleeding in joints, muscles, soft tissues, and within mucous membranes, which can be either spontaneous or due to internal or external trauma, depending on the severity of the disease. In the 7MM, GlobalData epidemiologists forecast an increase in the diagnosed prevalent...
  • 敗血症および敗血症性ショックの疫学予測（～2026年）
    GDHCER156-17 / GlobalData / 2017年8月1日 / ...EpiCast Report: Sepsis and Septic Shock - Epidemiology Forecast to 2026 Summary Sepsis is a life-threatening complication arising from an infection, which occurs when the body’s response to the infection damages its own tissues and organs. Sepsis can lead to multiple organ failure and death, especially if it is not recognized early and treated promptly. Anyone can develop sepsis; however, the condition is more common among children less than one year of age, older adults, and those with weakened immune systems. Although any type of infection (bacterial, viral, or fungal) can lead to sepsis, people suffering from pneumonia, abdominal infection,...
  • 急性骨髄性白血病（AML）治療薬の世界市場
    GDHC002FS / GlobalData / 2017年12月22日 / ...Acute Myeloid Leukemia (AML) - Dynamic Market Forecast to 2026 Summary Acute Myeloid Leukemia (AML) is a disease that has been characterized by a stagnant pipeline and, consequently, the treatment paradigm has not substantially changed over time. Since the 1970s, the standard of care in newly diagnosed fit patients has been a chemotherapy bases 7 + 3 induction regimen (seven days of cytarabine + three days of an anthracycline), aimed at achieving a complete hematologic remission (CR), followed by consolidation therapy with cytarabine, or an allogeneic hematopoietic cell transplantation (HCT). In the last decade, a better understanding of the molecular...
  • 慢性閉塞性肺疾患（COPD）の世界市場：疫学予測
    GDHCER152-17 / GlobalData / 2017年7月1日 / ...EpiCast Report: Chronic Obstructive Pulmonary Disease - Epidemiology Forecasts to 2025 Summary Chronic obstructive pulmonary disease (COPD), also known as chronic obstructive lung disease (COLD), is a condition characterized by difficulty in breathing, shortness of breath, wheezing, chest tightness, and other respiratory symptoms that progress over time. The disease is often caused by tobacco smoking; however, long-term exposure to other lung irritants, such as smoke from vehicle emissions and power stations, chemical fumes, and dust from the environment and workplace, can also contribute to the development of COPD (NHLBI, 2013). To forecast the total prevalent cases of COPD and the...
  • 急性骨髄性白血病(AML)：治療薬開発パイプライン動向（2016年下半期版）
    DATA70209230 / Global Markets Direct / 2016年12月28日 / 当調査レポートでは、世界における急性骨髄性白血病(AML)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル（説明、作用機序、研究開発の進展状況）などのデータをお届けいたします。 ・イントロダクション ・急性骨髄性白血病(AML)の概要 ・急性骨髄性白血病(AML)治療薬の開発 　　- パイプライン製品の概要 　　- パイプライン製品の比較分析 ・企業で開発中の治療薬 ・大学/研究機関で研究中の治療薬...Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Myelocytic Leukemia – Pipeline Review, H2 2016, provides an overview of the Acute Myelocytic Leukemia (Oncology) pipeline landscape. Acute myelocytic leukemia (AML), also known as acute myelogenous leukemia is a type of cancer that affects the blood and the bone marrow. Immature white blood cells accumulate in the bone marrow thus blocking the production of normal blood cells. These cells further enter the blood stream and spread to the other parts of the body. Symptoms for...
  • 2型糖尿病の疫学予測（～2026年）
    GDHCER154-17 / GlobalData / 2017年7月10日 / ...EpiCast Report: Type 2 Diabetes - Epidemiology Forecast to 2026 Summary Type 2 diabetes (T2D), formerly known as non-insulin dependent diabetes mellitus or adult-onset diabetes mellitus, is a chronic disorder of glucose equilibrium that results from the body’s inability to make use of available insulin along with relative insulin deficiency. T2D constitutes approximately 90-95% of all diabetes cases around the world, while type 1 diabetes and gestational diabetes make up the remaining 5-10% of cases. Lifestyle factors such as obesity, physical inactivity, and dietary habits are modifiable risk factors, and can therefore be controlled or prevented. Non-modifiable risk factors such...
  • 静脈血栓塞栓症（VTE）の世界市場：疫学予測
    GDHCER149-17 / GlobalData / 2017年6月1日 / ...EpiCast Report: Venous Thromboembolism - Epidemiology Forecast to 2026 Summary Venous thromboembolism (VTE), which is composed of deep vein thrombosis (DVT) and pulmonary embolism (PE), is a blood clot (thrombosis) of the circulatory system that leads to impeded blood flow, which can have serious consequences in affected individuals. VTE can occur at any age, but it is more common in adults ages 60 years and older and is very rare in children. VTE events are highly dangerous and are associated with high rates of mortality and morbidity. GlobalData epidemiologists forecast an increase in the diagnosed incident cases of VTE in...

    • ◆H&Iグローバルリサーチのお客様（例）◆